Evoke Pharma Inc (NAS:EVOK)
$ 4.3501 -0.0799 (-1.8%) Market Cap: 6.46 Mil Enterprise Value: 244,000.00 PE Ratio: 0 PB Ratio: 0.89 GF Score: 44/100

Evoke Pharma Inc KOL Webinar on HRCU Data Transcript

Jun 22, 2023 / 03:00PM GMT
Release Date Price: $18.84
Yale Jen
Laidlaw and Company - Analyst

Good morning. My name is Yale Jen, Senior Biotech Analyst of Laidlaw and Company. We appreciate your attending our fireside chat this morning to discuss the real world GIMOTI benefits over oral metoclopramide from the recent DDW digestive disease week meeting presentations. We will also have additional discussions of other relevant issue in treating gastroparesis with author, Dr. David Kunkel.

Overall, we believe this is the first major academic analysis providing a tangible and quantifiable benefit of GIMOTI's.

Let me begin first that we are very honored to have Dr. David C. Kunkel from UC San Diego to provide his analysis and discussion with us. He is an Associate Clinical Professor of Medicine and the board certified and the practicing gastroenterologist specializing in the diagnosis and the treatment of gastrointestinal motility disorders such as GERD, gastroparesis, bloating, and other disorders.

He is a member of the American Neurogastroenterology and Motility Society and was a recipient of the Training Award in mortality in 2013.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot